Stifel Reiterates ChemoCentryx (CCXI) at Buy, Stock Reaction is Overdone, Tavneos Outlook Unchanged
Tweet Send to a Friend
Stifel analyst Dae Gon Ha reiterated a Buy rating on ChemoCentryx (NASDAQ: CCXI), following the company's Q4 report. The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
